secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001549595-25-000043
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix appoints former Merck CMO Roy Baynes to board of directors
----------------------------------------------------------------

- Appoints Roy D. Baynes (EVP & CMO of Eikon, former Merck CMO) as Class II director, effective March 11, 2025.
- Received initial option for 50,000 shares vesting over 3 years; annual cash retainers of $50,000 (board) and $5,000 (committee).
- Served on Medical Advisory Board since 2023; will advise on clinical development including NX-5948 for CLL.
- No family relationships or material interests with directors/officers; standard indemnification agreement executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000043/0001549595-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000043/nrix-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer